anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Lung cancer is the leading cause of cancer-related death worldwide with Non-Small Cell Lung Cancer (NSCLC) being the most common subtype. Performance status deterioration due to progressive symptoms and toxicity by treatments are major challenges in managing advanced NSCLC patients. Moreover, standard treatment monitoring by radiologic scans is often imprecise. This technology has limited sensitivity as only a visible increase or decrease in tumor mass can be evaluated, making interpretation challenging and conclusions of whether patients benefit from treatment indefinite. Interpretation of radiologic scans has been further challenged after implementation of immunotherapy, causing immunotherapy-induced recruitment of immune cells resembling increment in tumor size, called "pseudo-progression." More sensitive methods are highly needed to reduce ineffective treatments and needless toxicity. Liquid biopsy has the potential to overcome these challenges by measuring molecular changes with high precision in a dynamic manner. Recent studies have demonstrated its promising potential as a biomarker predictive of treatment efficacy and overall survival. In a recent real-life study, investigators found that ctDNA measurements could reduce 33% of likely inefficient treatments and clarify 79% of non-conclusive CT-scans, highlighting the clinical potential. A randomized interventional multicenter study will be performed, investigating the true clinical potenial of liquid biopsy compared to standard monitoring by radiological scans. A total of 350 patients with advanced NSCLC will be included in the study from three Departments of Clinical Oncology. In the interventional arm, liquid biopsy monitoring will be the basis for treatment discontinuation before the standard two years of immunotherapy in patients reaching a complete molecular response in plasma. Thus clarifying the question if treatment duration can be reduced for the benefit of patients and health cost.
This cohort will include 150 patients at the time of the infection: Approximatively 75 patients will be drawn from the cohort of solid-organ transplant recipients included at day 0 of transplantation. Additional 75 patients developing a CMV infection will be also included.
Recently, we have introduced 3D-micro-patterned pharmaceutical dosage forms for enhancing the efficacy, safety, convenience, and cost-effectiveness of drug therapies. Presented herein are an apparatus and a method for the manufacture of such dosage forms. The apparatus comprises a first extruder for preparing a plasticized matrix of drug and excipient. The first extruder comprises an exit port having a valve mated to an input port of a second extruder. Said second extruder comprises a translatable piston for extruding plasticized fiber at controlled speed. The apparatus further comprises a stage movable at the controlled speed of the extruded fiber for depositing said fiber to a three dimensional structural framework. The method includes extruding plasticized matrix from a first extruder into a second extruder, extruding said plasticized matrix from the second extruder through a fiber fabrication exit port at controlled speed, and depositing said extruded fiber onto a fiber assembling stage to form a three dimensional structural framework.
BACKGROUND: Sepsis is a frequent reason for ICU admission and a leading cause of death. Its incidence has been increasing over the past decades. While hospital mortality is decreasing, it is recognized that the sequelae of sepsis extend well beyond hospitalization and are associated with a high mortality rate that persists years after hospitalization. The aim of this study was to disentangle the relative contribution of sepsis (infection with multi-organ failure), of infection and of inflammation, as reasons for ICU admission to long-term survival. This was done as infection and inflammation are both cardinal features of sepsis. We assessed the 3-year mortality of ICU patients admitted with sepsis, with individually matched ICU patients with an infection but not sepsis, and with an inflammatory illness not caused by infection, discharged alive from hospital.
METHODS: A multicenter cohort study of adult ICU survivors admitted between January 1st 2007 and January 1st 2019, with sepsis, an infection or an inflammatory illness. Patients were classified within the first 24 h of ICU admission according to APACHE IV admission diagnoses. Dutch ICUs (n = 78) prospectively recorded demographic and clinical data of all admissions in the NICE registry. These data were linked to a health care insurance claims database to obtain 3-year mortality data. To better understand and distinct the sepsis cohort from the non-sepsis infection and inflammatory condition cohorts, we performed several sensitivity analyses with varying definitions of the infection and inflammatory illness cohort.
RESULTS: Three-year mortality after discharge was 32.7% in the sepsis (N = 10,000), 33.6% in the infectious (N = 10,000), and 23.8% in the inflammatory illness cohort (N = 9997). Compared with sepsis patients, the adjusted HR for death within 3 years after hospital discharge was 1.00 (95% CI 0.95-1.05) for patients with an infection and 0.88 (95% CI 0.83-0.94) for patients with an inflammatory illness.
CONCLUSIONS: Both sepsis and non-sepsis infection patients had a significantly increased hazard rate of death in the 3 years after hospital discharge compared with patients with an inflammatory illness. Among sepsis and infection patients, one third died in the next 3 years, approximately 10% more than patients with an inflammatory illness. The fact that we did not find a difference between patients with sepsis or an infection suggests that the necessity for an ICU admission with an infection increases the risk of long-term mortality. This result emphasizes the need for greater attention to the post-ICU management of sepsis, infection, and severe inflammatory illness survivors.
COVID-19 is a potentially fatal respiratory illness, caused by the novel coronavirus, SARS-CoV-2, which developed into a pandemic claiming the lives of over 500,000 people in the United States and over 2.5 million worldwide. Antibodies against the spike glycoprotein are believed to confer immunity to SARS-CoV-2. Multiple sclerosis (MS) is an autoimmune disease of the central nervous system, which is typically treated with immunomodulating medications, referred to as disease modifying therapies (DMTs). Some DMTs resulted in a diminished capacity to develop antibodies against natural infection with SARS-CoV-2. This study is designed to evaluate and compare the effect of DMTs on antibody response to mRNA vaccines for COVID-19. Serum samples will be collected from 30 participants per treatment arm at 8 weeks, 24 weeks, 36 weeks, and 48 weeks, following vaccination with mRNA-1273. Geometric mean titers of anti-SARS-CoV-2 spike IgG will be measured to evaluate and compare peak antibody titers, as well as the duration of antibody response. The results will likely impact clinical decision-making, and guide treatment strategies for safely managing MS during the ongoing pandemic.
PROBLEM TO BE SOLVED: To obtain the subject agent capable of promoting keratinization of epithelial cells, by including silicic acid-related matter and calcium. SOLUTION: This agent is obtained by including silicic acid-related matter such as silicic acid, methasilicic acid, and orthosilicic acid, and salts thereof and calcium. It is preferable that an acid is included, together with the matter, to adjust the pH at 2-10 in case the silicic acid-related compound(s) is used as an epidermis keratinization-promoting medicine in the form of a solution such as a lotion. The silicic acid-related matter is formulated to the composition at 0.1-99 wt.% in case the agent is used in the form as preparation for external use for skin, cosmetic, bath preparation, or the like. It is preferable that a molar ratio of calcium to silicon is 10 or greater.  The agent thus prepared promotes keratinization of epithelial cells in the skin epidermal layer, improves the skin barrier function, and is useful to treat skin diseases such as atopic dermatitis, psoriasis, xerodermia, body skin roughness, scurf, and lip skin roughness.
This invention provides a monoclonal antibody which specifically recognizes and forms a complex with a protein located on the surface of activated T cells and thereby inhibits T cell activation of B cells. This invention also provides the monoclonal antibody 5c8 (ATCC Accession No. ______).  
     This invention provides a human CD4 −  T cell leukemia cell line designated D1.1 (ATCC Accession No. ______) capable of constitutively providing contact-dependent helper function to B cells. This invention also provides an isolated protein from the surface of activated T cells, wherein the protein is necessary for T cell activation of B cells. This invention further provides an isolated, soluble protein from the surface of activated T cells, wherein the protein is necessary for T cell activation of B cells.
PURPOSE:To obtain stable suspension-type preparation of rectal administration, by irradiating supersonics to melt mixture composed of drug hardly soluble to base material of suppository, base material of suppository and additive and uniformly suspending and dispersing. CONSTITUTION:A mixture composed of a drug hardly soluble to a fat-soluble and water-soluble base material of suppository, a base material of suppository and additive (e.g., surfactant, perfume, coloring matter or filler) is molten. Melting temperature is 40-60 deg.C in the case of fat-soluble base material and 60-80 deg.C in the case of water-soluble base material. Next, supersonic of 18-44kHZ frequency is irradiated to the molten mixture for >=5min. Then, the mixture is charged into a suppository container by conventional method, cooled and shaped to afford the aimed preparation. Bromazepam or diclofenac sodium, etc., is used as a drug.
As critical regulators of blood-brain barrier (BBB) function and tissue perfusion, endothelial cells are vital for cerebrovascular function and adaptation to stress and thus for brain health. Stimulation or normalization of cerebrovascular function may improve outcome of both acute and chronic central nervous system disorders. The circulating lipid mediator sphingosine-1-phosphate (SIP) sustains both EC functions and lymphocyte egress through the SlP1 receptor in other organs. The inventors report that EC SIP 1  signaling is also essential for cerebral blood flow, BBB function, and anti-inflammatory properties of the brain endothelium in naive mice, and that signaling expands during ischemia. Importantly, endothelial SIP 1  is polarized to the abluminal surface of most brain endothelial cells, shielding the receptor from circulating endogenous and synthetic ligands in the mature brain. As a consequence, endothelial cell autonomous SIP provision is required to sustain endothelial SIP 1  signaling and endothelial function in ischemic stroke, and BBB-penetration is required for SIP 1  agonists to engage the receptor at the BBB. Targeting of SIP 1  with selective BBB-penetrating agonists was shown to limit cortical infarct expansion with or without reperfusion when applied up to 6 hours after MCA occlusion. Thus, the present invention relates to methods for stimulating cerebrovascular function in patients suffering from ischemic stroke, intracerebral hemorrhage, or central nervous system disorders associated with cerebrovascular dysfunction.
Quinine is added to heated cod-liver oil fatty acids (morrhuic acid) forming quinine morrhuate.  Fatty acids of other animal or vegetable oils, e.g. olive, cottonseed or castor oil, or oleic acid may be used similarly.ALSO:A solution for injection in the treatment of varicose veins is prepared by making a solution of free quinine in an aqueous medium containing the sodium salt of a fatty acid obtainable from natural fats and oils.  The quinine may be dissolved in hot benzyl alcohol and the solution mixed with hot aqueous sodium morrhuate, the product containing 5 or 10 per cent sodium morrhuate, and 2 per cent each of quinine and alcohol.  Alternatively, the quinine is added to the free fatty acids of cod-liver oil and aqueous sodium hydroxide added to give a pH of 8-10.  Benzyl alcohol may be added.  Fatty acids of vegetable or animal oils, e.g. olive, cottonseed or castor oil, or oleic acid, or their sodium salts may be used similarly.
Described herein are interleukin-18 receptor binding moieties and uses thereof. An interleukin-18 receptor binding moiety can be an interleukin-18 receptor agonist or antagonist. An interleukin-18 receptor agonist can be an interleukin-18 receptor alpha binding moiety, an interleukin-18 receptor beta binding moiety, or can include interleukin-18 receptor alpha binding moiety and an interleukin-18 receptor beta binding moiety. An interleukin-18 receptor antagonist can be an interleukin-18 receptor alpha binding moiety, an interleukin-18 receptor beta binding moiety, or can include interleukin-18 receptor alpha binding moiety and an interleukin-18 receptor beta binding moiety. Interleukin-18 receptor agonists and interleukin-18 receptor antagonists can be formulated in a pharmaceutical formulation. Interleukin-18 receptor agonists and interleukin-18 receptor antagonists are useful for treating diseases and disorders in a subject in need thereof.
Postmarketing cases of non-cirrhotic portal hypertension have been reported, including cases leading to liver transplantation or death. Cases of didanosine-associated non-cirrhotic portal hypertension were confirmed by liver biopsy in patients with no evidence of viral hepatitis. Onset of signs and symptoms ranged from months to years after start of didanosine therapy. Common presenting features included elevated liver enzymes, esophageal varices, hematemesis, ascites, and splenomegaly. 

Patients receiving didanosine delayed-release capsules should be monitored for early signs of portal hypertension (eg, thrombocytopenia and splenomegaly) during routine medical visits. Appropriate laboratory testing including liver enzymes, serum bilirubin, albumin, complete blood count, and international normalized ratio (INR) and ultrasonography should be considered. Didanosine delayed-release capsules should be discontinued in patients with evidence of non-cirrhotic portal hypertension.
PURPOSE: Provided is beef leg bone stock with Polygonatum japonicum auct. Korea which is effective for prevention and treatment of cancers. It reduces cancer occurrence compared to beef leg bone stock. CONSTITUTION: The beef leg bone stock with Polygonatum japonicum auct. Korea is characterized by using beef bone and Polygonatum japonicum auct. Korea as main ingredients. It further uses perilla seed, jujube, chest nut, ginseng, Codonopsis lanceolata, Angelica gigas Nakai, Polygonum multiflorum, garlic and glutinous rice.
Bradycardia is a commonly occurring condition in premature infants, often causing serious consequences and cardiovascular complications. Reliable and accurate detection of bradycardia events is pivotal for timely intervention and effective treatment. Excessive false alarms pose a critical problem in bradycardia event detection, eroding trust in machine learning (ML)-based clinical decision support tools designed for such detection. This could result in disregarding the algorithm's accurate recommendations and disrupting workflows, potentially compromising the quality of patient care. This article introduces an ML-based approach incorporating an output correction element, designed to minimise false alarms. The approach has been applied to bradycardia detection in preterm infants. We applied five ML-based autoencoder techniques, using recurrent neural network (RNN), long-short-term memory (LSTM), gated recurrent unit (GRU), 1D convolutional neural network (1D CNN), and a combination of 1D CNN and LSTM. The analysis is performed on ∼440 hours of real-time preterm infant data. The proposed approach achieved 0.978, 0.73, 0.992, 0.671 and 0.007 in AUC-ROC, AUC-PRC, recall, F1 score, and false positive rate (FPR) respectively and a false alarms reduction of 36% when compared with methods without the correction approach. This study underscores the imperative of cultivating solutions that alleviate alarm fatigue and encourage active engagement among healthcare professionals.
The invention relates to a medical and beauty dressing film with high oxygen permeability and a preparation technology thereof. The film is made of rubber materials commonly used in medicine: silica gel and polyurethane, etc. Respectively coating a rubber material liquid and a curing agent liquid on one surface of each of 2 nano molds, respectively scraping off redundant liquid and rolling, then oppositely stacking the coating liquid surfaces of the two molds, and then rolling, heating, curing and defoaming to form the film with hole arrangement. Because the processing modes of rolling and heating are mainly adopted, the cost is greatly reduced, the efficiency is improved, and the large-scale stable production is facilitated. Compared with the existing film formed by randomly superposing the nanofibers prepared by electrostatic spinning and high-pressure airflow and randomly weaving, the preparation technology further improves the oxygen permeability of the medical film due to the pore nano structure which is regularly and uniformly arranged. The product prepared by the technology has wide application prospect in the fields of medical dressing, beauty concealer, flexible electronics, wearable technology and the like.
Lysostaphin is demonstrated to be a powerful anti-staphylococcal agent suitable for parenteral administration to mammals including humans. Low dosages, in the order of 0.5 - 45 mg/kg/day are sufficient to eradicate most staphylococcal infections. Lysostaphin is also effective against bacteria of this type that have developed resistance to conventional antibiotics such as penicillins and vancomycin. Lysostaphin analogues, such as variants and related enzymes, show similar activity. The figure shows a graph reflecting the bactericidal activity of lysostaphin against a variety of S. aureus strains of differing antimicrobial resistance. These data demonstrate that lysostaphin has potent and rapid bactericidal activity against contemporary clinical isolates of S. aureus, including strains resistant to methicillin and strains both resistant to methicillin and intermediately resistant to vancomycin.
A single oral dose of diclofenac (25 mg capsule) and a single oral dose of curcumin (2,000 mg tablet) will be administered by mouth to the 5 participants genotyped as extensive metabolizers. Plasma and urine will be collected from 0-12 hours.
Plantar fasciitis is one of the most common foot conditions presenting to a foot and ankle specialist. Surgical treatment outcomes following plantar fasciotomy vary but short-term studies have reported excellent early pain relief and significant improvements in symptoms. This study evaluates patient reported pain scores collected pre- and post-op for patients who underwent percutaneous ultrasonic microtenotomy (PUT) plantar fasciotomy with PRP injection vs without the use of PRP. We compared pain visual analog scale (VAS) scores, for patients treated surgically by Orthopedic Surgery department of foot and ankle faculty members between December 2007 and December 2022. A total of 30 patients were identified that met inclusion and exclusion criteria. Our results showed that there was a significant decrease in pain VAS scores from pre-op visit (at least 1 month prior to operation) to post-op visit (at least 1 month following operation) for both groups, with a paired t test (p value <.0001). However, patients who received PRP had a statistically significant decrease in pain level compared to the group who did not receive PRP. Statistical analysis completed with a 2-sample t test (p-value <.0325). Our results found the mean time between the initial pre-op visit and last post-op follow-up visit was 19 months. The mean for time following surgical intervention was 10 months. The findings of our study suggest that the dual use of PUT and PRP to treat plantar fasciitis, could potentially lead to an improvement in pain reduction and longevity of pain relief.
Sessions of intermittent hypoxia at rest; 3 sessions/week; 8 weeks. To be compared with the placebo (normoxia) group at rest.
Alcohol use is associated with a number of adverse health and economic effects. Problem drinking is associated with increased mortality rates and with premature mortality. As a result of these findings, the testing of the effectiveness of alcohol abuse prevention strategies has become an important national research priority. Secondary prevention of alcohol problems covers the methods used for early detection and treatment of people with excessive alcohol consumption. These preventive methods are referred to as brief interventions. Brief intervention is a short-term counseling strategy based on motivational enhancement therapy that concentrates on changing patient behavior and increasing patient compliance with therapy. It has been shown to be effective for helping socially stable problem drinkers to reduce or stop drinking, for motivating alcohol-dependent patients to enter long-term alcohol treatment, and for treating some alcohol-dependent patients for whom the goal is abstinence. The aims of this study are to examine the outcomes of a brief intervention to reduce alcohol consumption by problem drinkers among medical inpatients in general hospital setting. The study design is a randomized controlled clinical trial. Patients will be recruited from adult patients who are admitted to medical or surgical wards of a general hospital. All adult inpatients of a general hospital, aged 18 to 65 years, will be consecutively screened with the Alcohol Use Disorders Identification Test for identifying the problem drinkers. All patients who screen positive and who have signed a consent form will be contacted by a researcher and invited to participate in a face-to-face interview to determine their eligibility for the trial. The inclusion criteria are problems drinkers, defined as men who drank more than 21 units a week and women who drank more than 14 units a week. Patients will be excluded from participation in the study if they are younger than 18 years or older than 65 years, and have attended an alcohol treatment program in the last 3 months. Screened positives will then be interviewed using the instrument of SCAN to confirm the diagnosis of alcohol use disorders. The patients who fulfill the criteria will be randomized into one of the three following groups: (1) control group will be provided with routine inpatient usual care; (2) experimental group 1: physicians and nurses in charge will be informed of the results of alcohol consumption screening, in addition to providing routine inpatient usual care; (3) experimental group 2 will receive brief intervention, in addition to treatment protocols provided for experimental group 1. Brief intervention, offered twice by well-trained therapists, is 15-minute short-term individual consultation, giving alcohol health education, increasing their motivation to alcohol abstinence, teaching alcohol abstinence principle, and in order to ameliorate the over-drinking problems in these cases. The main outcome measures are alcohol use measures, which will be evaluated at 12-week after the study recruitment.